NO20072035L - Memantin for behandling av adferdsforstyrrelser hos barn - Google Patents

Memantin for behandling av adferdsforstyrrelser hos barn

Info

Publication number
NO20072035L
NO20072035L NO20072035A NO20072035A NO20072035L NO 20072035 L NO20072035 L NO 20072035L NO 20072035 A NO20072035 A NO 20072035A NO 20072035 A NO20072035 A NO 20072035A NO 20072035 L NO20072035 L NO 20072035L
Authority
NO
Norway
Prior art keywords
memantine
children
treatment
behavioral disorders
disorder
Prior art date
Application number
NO20072035A
Other languages
English (en)
Inventor
Sandeep Gupta
Jeffrey Jonas
Pradeep K Banerjee
Allison Mann
Hans-Joerg Moebius
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35445934&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072035(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of NO20072035L publication Critical patent/NO20072035L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer en fremgangsmåte for behandling av individer diagnostisert med en atferdsforstyrrelse i barndommen, f.eks. en forstyrrelse innen autismespektret eller oppmerksomhetssvikt/hyperaktivitetsforstyrrelse (ADHD) av kombinert type, ved tilførsel av en effektiv mengde memantin.
NO20072035A 2004-09-23 2007-04-20 Memantin for behandling av adferdsforstyrrelser hos barn NO20072035L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61260004P 2004-09-23 2004-09-23
PCT/US2005/034199 WO2006034465A1 (en) 2004-09-23 2005-09-23 Memantine for the treatment of childhood behavioral disorders

Publications (1)

Publication Number Publication Date
NO20072035L true NO20072035L (no) 2007-06-13

Family

ID=35445934

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072035A NO20072035L (no) 2004-09-23 2007-04-20 Memantin for behandling av adferdsforstyrrelser hos barn

Country Status (16)

Country Link
US (2) US20060079582A1 (no)
EP (1) EP1799224A1 (no)
JP (1) JP2008514620A (no)
KR (1) KR20070046185A (no)
CN (1) CN101374525A (no)
AR (1) AR052643A1 (no)
AU (1) AU2005286672B2 (no)
BR (1) BRPI0515560A (no)
CA (1) CA2578953A1 (no)
EA (1) EA012036B1 (no)
IL (1) IL182105A0 (no)
MX (1) MX2007003267A (no)
NO (1) NO20072035L (no)
TW (1) TW200626160A (no)
WO (1) WO2006034465A1 (no)
ZA (1) ZA200702130B (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7456224B2 (en) 2004-04-05 2008-11-25 Forest Laboratories Holdings, Ltd. Method for treating autism
WO2008005534A2 (en) * 2006-07-06 2008-01-10 Forest Laboratories, Inc. Orally dissolving formulations of memantine
RU2326660C1 (ru) * 2007-03-14 2008-06-20 Закрытое акционерное общество "Биологические исследования и системы" Пероральный лекарственный препарат мемантин (варианты) и способ его получения (варианты)
WO2009004440A2 (en) * 2007-06-29 2009-01-08 Orchid Chemicals & Pharmaceuticals Limited Quick dissolve compositions of memantine hydrochloride
US20090247644A1 (en) * 2008-03-28 2009-10-01 Forest Laboratories Holdings Limited Memantine formulations
EP2138173A1 (en) 2008-06-26 2009-12-30 Merz Pharma GmbH & Co.KGaA Pharmaceutical compositions comprising aminoadamantane derivatives
EP2201950B1 (en) * 2008-12-08 2016-11-16 Biocodex Compounds and methods for treating autism spectrum disorders
IT1396556B1 (it) * 2009-02-11 2012-12-14 Serra Uso di memantina per il trattamento di disturbi dell umore
DK3034079T3 (en) 2010-11-15 2018-02-05 Agenebio Inc PYRIDAZINE DERIVATIVES, COMPOSITIONS AND PROCEDURES FOR TREATING COGNITIVE WEAKNESS
RU2488388C1 (ru) * 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
US9242009B2 (en) 2012-07-17 2016-01-26 The General Hospital Corporation Compositions and methods to treat neurodegenerative diseases
UA107653U (uk) * 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
KR101424514B1 (ko) * 2013-01-02 2014-07-31 건국대학교 산학협력단 선천성 발프로산 노출 증후군 치료제로서의 메만틴의 용도
EP2948135B1 (en) * 2013-01-25 2019-01-02 Case Western Reserve University Compositions and methods for the treatment of pervasive development disorders
WO2014153180A1 (en) * 2013-03-14 2014-09-25 Michela Gallagher Methods and compositions for improving cognitive function
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
CN112409363B (zh) 2013-12-20 2023-11-14 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂䓬衍生物、组合物和方法
NZ776366A (en) * 2015-05-22 2023-02-24 Univ Minnesota Methods for treating autism spectrum disorder and associated symptoms
WO2016205739A1 (en) 2015-06-19 2016-12-22 Belew Mekonnen Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
RU2021106383A (ru) 2016-08-24 2021-04-05 Зодженикс Интернэшнл Лимитед Состав для ингибирования образования агонистов 5-ht2b и способы его применения
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11529319B2 (en) 2017-08-01 2022-12-20 Stuart A. Lipton Methods and compositions for treating neurological conditions
US20190091179A1 (en) * 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
JP7543136B2 (ja) 2017-11-22 2024-09-02 パノラマ リサーチ，インコーポレイティド Ｃｎｓ疾患を治療するためのアミノアダマンチルナイトレート化合物およびそれらの使用
FR3075038B1 (fr) 2017-12-15 2020-03-06 Melchior Material And Life Science France Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete
BR112020026062B1 (pt) 2018-06-19 2023-04-04 Agenebio, Inc Compostos derivados de benzodiazepina ou um sal farmaceuticamente aceitavel, isômero ou combinação dos mesmos, composição farmacêutica compreendendo os mesmos e usos dos mesmos para o tratamento de comprometimento cognitivo, câncer cerebral e psicose da doença de parkinson
EA202191079A1 (ru) 2018-11-19 2021-09-20 Зодженикс Интернэшнл Лимитед Способы лечения синдрома ретта с применением фенфлурамина
KR20230137978A (ko) * 2021-02-03 2023-10-05 더 제너럴 하스피탈 코포레이션 자폐증 스펙트럼 장애를 치료하는 방법
KR20250136397A (ko) * 2023-01-27 2025-09-16 하이로리스 디벨롭먼츠 에스에이 쓴맛 약물을 위한 맛 차폐제로서 비타민 e tpgs 의 용도

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH603545A5 (no) * 1972-04-20 1978-08-31 Merz & Co
HU169986B (no) * 1972-12-07 1977-03-28
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
US5811128A (en) * 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US4849222A (en) * 1987-03-24 1989-07-18 The Procter & Gamble Company Mixtures for treating hypercholesterolemia
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
ES2059602T3 (es) * 1989-04-14 1994-11-16 Merz & Co Gmbh & Co Uso de derivados de adamantano para la prevencion y tratamiento de isquemia cerebral.
US4994467A (en) * 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
US6326226B1 (en) * 1997-07-15 2001-12-04 Lg. Philips Lcd Co., Ltd. Method of crystallizing an amorphous film
EP1047436B1 (en) * 1998-01-13 2009-10-21 Synchroneuron, LLC N-acetylhomotaurinates for use in treating hyperkinesias
WO2001041707A2 (en) * 1999-12-08 2001-06-14 Vanderbilt University Modulation of in vivo glutamine and glycine levels in the treatment of autism
US6727231B1 (en) * 2000-10-12 2004-04-27 Repligen Corporation Uridine therapy for patients with elevated purine levels
CA2473536A1 (en) * 2002-01-16 2003-07-31 Endo Pharmaceuticals, Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
EP1523309A2 (en) * 2002-07-19 2005-04-20 Khalid Iqbal Nmda receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease

Also Published As

Publication number Publication date
IL182105A0 (en) 2007-07-24
EA200700708A1 (ru) 2007-08-31
US20060079582A1 (en) 2006-04-13
CN101374525A (zh) 2009-02-25
BRPI0515560A (pt) 2008-07-29
EP1799224A1 (en) 2007-06-27
MX2007003267A (es) 2007-05-23
US20100081723A1 (en) 2010-04-01
WO2006034465A1 (en) 2006-03-30
JP2008514620A (ja) 2008-05-08
WO2006034465A8 (en) 2006-06-08
CA2578953A1 (en) 2006-03-30
AU2005286672A1 (en) 2006-03-30
EA012036B1 (ru) 2009-06-30
TW200626160A (en) 2006-08-01
AU2005286672B2 (en) 2009-03-12
AR052643A1 (es) 2007-03-28
ZA200702130B (en) 2008-09-25
KR20070046185A (ko) 2007-05-02

Similar Documents

Publication Publication Date Title
TW200626160A (en) Memantine for the treatment of childhood behavioral disorders
NO20062003L (no) Fremgangsmate og forbindelser for behandling av immunoinflammatoriske forstyrrelser
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
WO2007100777A3 (en) Methods for the treatment of adhd and related disorders
NO20083147L (no) Anti-OX40L-antistoffer og fremgangsmater for anvendelse av disse
BR112014018592A2 (pt) composição e método para o diagnóstico e tratamento de doenças associadas à degeneração de neuritos
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
UY31114A1 (es) Anticuerpos humanizados contra el globulómero ab(20-42) y sus usos
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
MY177564A (en) Anti-nr10 antibody and use thereof
EA201270184A1 (ru) Лечение расстройств печени ингибиторами pi3k
BRPI0916576A2 (pt) pelo menos uma entidade química, composição farmacêutica, e, método para tratar uma condição ou distúrbio.
PL1974210T3 (pl) Sposób diagnozowania wielotorbielowatości nerek
CY1110620T1 (el) Μεθοδος θεραπειας οξειας παραρρινοκολπιτιδας
WO2006014638A3 (en) ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
BRPI0416812A (pt) métodos e reagentes para o tratamento de desordens inflamatórias
WO2008100727A3 (en) High-dose glycine as a treatment for obsessive-compulsive disorder and obsessive-compulsive spectrum disorders
WO2006059252A3 (en) Methods and fluorinated compositions for treating amyloid-related diseases
ATE454465T1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
CY1116166T1 (el) Νεα μεθοδος για την αντιμετωπιση λοιμωξεων απο η.pylori
TW200740441A (en) Methods and reagents for the treatment of inflammatory disorders
EP1899726A4 (en) METHODS FOR DIAGNOSING AND TREATING CEREBROVASCULAR EVENTS BASED ON NR2 PEPTIDES
MX2020002008A (es) Tratamientos antivirales intravenosos.
WO2007095352A3 (en) Diagnosis and treatment of attentional disorders

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application